Keywords: Zeltia, Lurrbinectedin, Ovarian cancer, Licensing potential, Yondelis, Valuation

Spain's Zeltia is turning a corner, say Edison analysts

Article | 28 February 2013

Print This

Spanish drugmaker Grupo Zeltia (ZEL: MC) is approaching a material catalyst this year in the form of the read-out from ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in